DrugBiological
Sonepcizumab clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Lpath, Inc. (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sonepcizumab is read from its arms, and is right about nine times in ten.
Testing it · 5
- Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMDCompletedPhase 2Lpath, Inc.NCT01414153Written as 4.0 mg iSONEP
- A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell CarcinomaTerminatedPhase 2Lpath, Inc.NCT01762033Written as ASONEP
- iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)TerminatedPhase 1Lpath, Inc.NCT01334255Written as iSONEP (sonepcizumab/LT1009)
- Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular DegenerationStatus unknownPhase 1Lpath, Inc.NCT00767949Written as iSONEP
- Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid TumorsCompletedPhase 1Lpath, Inc.NCT00661414Written as ASONEP (sonepcizumab/LT1009)
Codes
What other systems call sonepcizumab · ClinicalTrials.gg INT000686
- MeSH (NLM) C000619670sonepcizumabOne source NLM
- UNII (FDA) O4T5UXS4P2SONEPCIZUMABConfirmed FDA, NLM
- NCI Thesaurus C78195SonepcizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619670 | sonepcizumab | One source NLM |
| UNII (FDA) | O4T5UXS4P2 | SONEPCIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C78195 | Sonepcizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.